Medibio Broadens Opportunities with Compatibility to Fitbit Wearable Devices for Mental Health Measurement
Fitbit joins Apple Watch, Garmin and others allowing users to help process biometric data for an objective view of mental health
SYDNEY, Australia and MINNEAPOLIS, June 13, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (ASX:MEB) (OTCQB:MDBIF), the world leader in objective measurement technology for mental health, has recently enhanced the compatibility of its mobile app product to accept data from Fitbit devices equipped with heart rate monitors.
The mobile app, named Medibio Inform, allows businesses to offer employees the chance to 'check-in on their mental health' through a comprehensive mental health and wellness program that starts with an employee-facing, Mental Health Check-In campaign. This allows employees of participating businesses using Fitbit devices to assess their mental health using both traditional assessments and biometric measures. At this time, only Fitbit users that are enrolled in a Mental Health Check-In with their employer have access to use the Inform app.
Via the Inform app, Fitbit users will be able to process specific biometric features to create an objective view of their overall health. Once the user has authorized Medibio to access their Fitbit account, the Inform app then pulls in the sleep, activity and heart rate data that is associated with the user's wearable account. Medibio uses its proprietary platform and algorithms to process the biometric data and reports to the user on a daily basis.
The additional compatibility of Inform working with data from more than 25 million Fitbit wearable technologies, along with already accepted compatibility with nearly 13 million Garmin devices, is timely as the company prepares for the general consumer availability coming later in 2018.
"We're thrilled to give Fitbit users the ability to monitor their personal, objective biometric data to help manage their overall mental health and well-being," said Jack Cosentino, CEO of Medibio. "With the addition of Fitbit to our portfolio of compatible wearables, this strengthens our footprint in the market, and supports our goal to make our technology accessible to as many consumers as possible."
Medibio's Fitbit-compatible app is available in the App Store and Google Play today for compatible Fitbit devices. For more information, visit the company's website at www.medibio.com.au .
About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Perth (WA), and Minneapolis, MN (U.S.). Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au .
| Further Information:
| Press Inquiries:
T: 952-222-0551 ext. 204
| Australian Media Enquiries:
T: +61 475 792 917 // +61 2 8297 1503
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
GlobeNewswire Heartbeat Service25.5.2019 15:41:08 CEST | Pressemeddelelse
Test Release - 25-05-2019 - 211089
Biome Grow Inc.24.5.2019 19:10:55 CEST | Pressemeddelelse
Biome Grow Inc. to Announce First Quarter Fiscal 2019 Financial Results.
CGAP24.5.2019 17:06:19 CEST | Pressemeddelelse
Jason Lamb of Gates Foundation Named New Chair of CGAP’s Executive Committee
Collibra23.5.2019 15:01:20 CEST | Pressemeddelelse
Collibra Announces 2019 Excellence Awards Winners
XBiotech Inc.23.5.2019 14:21:06 CEST | Pressemeddelelse
XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa
Merus N.V.23.5.2019 14:02:11 CEST | Pressemeddelelse
Merus Announces 2019 Annual General Meeting of Shareholders
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum